Overview

LAG3 PET Imaging in Advanced Solid Tumors

Status:
Not yet recruiting

Trial end date:
2024-01-01

Target enrollment:

Participant gender:

Summary

This is an investigator-initiated, single-center, open-label clinical trial designed to evaluate the safety and PK of the PET tracer 89Zr-DFO-REGN3767 in patients prior to and during treatment.

Phase:

Phase 1/Phase 2

Details

Lead Sponsor:

University Medical Center Groningen

Collaborator:

Regeneron Pharmaceuticals

Treatments:

Cemiplimab